

Attorney Docket No.: 5347.210-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Andersen et al

Confirmation No: 6030

Serial No.: 09/816721

Group Art Unit: 1652

Filed: March 22, 2001

Examiner: Rao

For: Novel Cyclomaltodextrin Glucanotransferase Variants

11/c  
P.G.  
6/5/03

**AMENDMENT UNDER 37 C.F.R. 1.111**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed January 8, 2003, please amend the above-identified application as follows:

Attorney Docket No.: 5347.210-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Andersen et al

Confirmation No: 6030

Serial No.: 09/816721

Group Art Unit: 1652

Filed: March 22, 2001

Examiner: Rao

For: Novel Cyclomaltodextrin Glucanotransferase Variants

**FAX RECEIVED**  
**JUN 03 2003**  
**GROUP 1600**

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**OFFICIAL**

Sir:


I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment
3. Terminal Disclaimer to Obviate a Double Patenting Rejection Over a Prior Patent

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Rao, fax number (703).308-4242

Respectfully submitted,

Date: June 3, 2003



Lourdes Ayala  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097